Home » Topics » Regulatory » EMA

EMA
RSS

FDA and EMA accept regulatory submissions for dacomitinib

April 5, 2018

EMA validates MAA for Lynparza in BRCA-mutated HER2-negative metastatic breast cancer

April 4, 2018

EMA accepts Dupixent submission in asthma

April 3, 2018

EMA accepts cemiplimab MAA for cutaneous squamous cell carcinoma

April 3, 2018

Lanadelumab submissions in E.U. and Canada accepted for review

March 29, 2018

EMA accepts BioMarin's MAA for pegvaliase to treat adults with PKU

March 29, 2018

EMA validates application for Cabometyx for previously treated advanced HCC

March 28, 2018

EMA committee recommends approval of new dosing schedules for Opdivo in E.U.

March 27, 2018

EMA grants PRIME designation for lumasiran in primary hyperoxaluria type 1

March 27, 2018

CHMP supports conditional marketing authorization for Clovis Oncology's Rubraca

March 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...